Industry Supported Sessions Programs

Industry Supported Sessions Programs

Friday, March 16, 2018

 

11:45 – 13:25

Sala 500

THE EMERGING PICTURE OF EARLY ALZHEIMER'S DISEASE: IT'S ABOUT TIME

Symposium Organized by:

BIOGEN

CHAIR: José Molinuevo, USA

11:45                 WELCOME AND INTRODUCTION
 José Molinuevo, Spain

11:50                CASE STUDY PART 1: PATIENT PRESENTATION – HISTORIC SIGNS AND SYMPTOMS OF EARLY ALZHEIMER'S DISEASE
José Molinuevo, Spain

12:00                NEUROPSYCHOLOGICAL TOOLS: ASSESSMENT OF THE APPROPRIATE COGNITIVE DOMAINS IN THE DIAGNOSIS OF EARLY ALZHEIMER'S DISEASE
James Galvin, USA

12:10                CASE STUDY PART 2: NEUROPSYCHOLOGICAL RESULTS FOR A PATIENT WITH EARLY ALZHEIMER'S DISEASE
José Molinuevo, USA              

12:30                CASE STUDY PART 3: REVISED BIOMARKER ASSESSMENT – EVALUATION OF DISCORDANT BIOMARKERS IN THE DIAGNOSIS OF EARLY ALZHEIMER'S DISEASE
Lucilla Parnetti, Italy and and Jonathan Schott, UK

12:40                BIOMARKERS IN THE EVALUATION OF EARLY ALZHEIMER'S DISEASE: A COMPARISON OF AMYLOID PET AND CSF
Lucilla Parnetti, Italy and and Jonathan Schott, UK

13:00                CASE STUDY PART 4: BACK TO THE EVIDENCE – MAKING A DIAGNOSIS
José Molinuevo, USA                                               

13:05                PATIENT MANAGEMENT IN EARLY ALZHEIMER'S DISEASE: STRATEGIES AND SUPPORT FOR PATIENTS, FAMILIES AND CARE PARTNERS 
Wiesje van der Flier, The Netherlands

13:20                SUMMARY AND CLOSE
José Molinuevo,USA

 

 Saturday, March 17, 2018

 

08:45 – 10:45

Sala 500

PARKINSON'S DISEASE PERSONALIZED MEDICINE: GBA AND LRRK2 

Symposium Organized by:

SANOFI

CHAIRS: Laurent Pradier, France and Tanya Fischer, USA

08:45                GENETICS OF PD: THE EXAMPLE OF GBA AND LRRK2
 Stefano Goldwurm, Italy

09:06                THE ROLE OF GBA IN PARKINSON'S DISEASE
Pablo Sardi, USA

09:31                NEW TREATMENTS IN GBA PD
Nir Giladi, Israel

09:56                CAN BIOMARKERS INFORM DESIGN OF DISEASE MODIFICATION TRIALS? PPMI DATA MINING
Tatanya Simuni, USA

10:21                LRRK2 INHIBITORS FOR TREATING LRRK2-LINKED PD
Andy West, USA

 

 

11:15 – 12:55

Sala 500

ALZHEIMER'S DISEASE MODIFYING THERAPIES: IS IT TIME TO MOVE BEYOND THE AMYLOID CASCADE?

Symposium Organized by:

Lilly

CHAIR: To be advised

11:15                WELCOME AND INTRODUCTION

11:20                THE AMYLOID CASCADE: MUST DISEASE MODIFICATION BEGIN THERE?

11:45                POTENTIAL DOWNSTREAM EFFECTS OF AMYLOID TARGETED THERAPIES

12:10                ALZHEIMER'S DISEASE TREATMENT STRATEGIES AND POTENTIAL BENEFIT: RISK

12:35                PANEL DISCUSSION AND CONCLUSIONS

All

 

 

 

 

 

 



Keep Me Updated